Hester Biosciences Quarterly Results
Hester Biosciences quarterly results. In Sept 2026, Hester Biosciences (HESTERBIO) reported revenue ₹102 Cr and net profit ₹21 Cr — revenue +22.9% YoY. View HESTERBIO 52-week high low for the annual high/low range and current price position.
HESTERBIO Quarterly Results — Revenue, Profit & EPS Highlights
Hester Biosciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Hester Biosciences stock price NSE.
- Revenue of ₹102 Cr in Sept 2026 (+0.0% vs Mar 2026, +22.9% vs Sept 2025)
- Net Profit of ₹21 Cr in Sept 2026 (+23.5% vs Mar 2026, +50.0% vs Sept 2025)
- EBITDA of ₹37 Cr in Sept 2026 (+2.8% vs Mar 2026)
- Operating Margin of 33.0% in Sept 2026 (-1.0pp vs Mar 2026)
- Earnings Per Share of ₹23.94 in Sept 2026 (+23.1% vs Mar 2026)
Hester Biosciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
HESTERBIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 102 | 102 | 166 | 83 | 76 | - | 22.9% |
| Net Profit (₹ Cr) | 21 | 17 | 97 | 14 | 2 | - | - |
| EBITDA (₹ Cr) | 37 | 36 | 112 | 24 | 14 | - | - |
| EPS (₹) | 23.94 | 19.45 | 113.71 | 16.85 | 1.82 | - | - |
| Operating Margin (%) | 33.0% | 34.0% | 29.0% | 17.0% | 23.0% | - | - |
HESTERBIO Share Price Trend — 1-Year Movement Across Quarterly Results
Hester Biosciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore HESTERBIO share price history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
HESTERBIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Hester Biosciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1900.0 | 16,617 | 1,995 | +10.6% | - | 12.0% | 228.9 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11178.0 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4611.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 400.6 |
|
Apollo Hospitals
Sept 2026 |
₹126,832.45 Cr | 8738.0 | 7,673 | 660 | +15.2% | - | 8.6% | 199.4 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2306.0 | 2,219 | 436 | +21.7% | - | 19.6% | 282.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores